AIM ImmunoTech (AIM) Asset Writedowns and Impairment (2011 - 2025)
AIM ImmunoTech's (AIM) quarterly Asset Writedowns and Impairment came in at $441000.0 in Q4 2025, up 21950.0% YoY from N/an in Q4 2024, and up 437.8% on a QoQ basis from $82000.0 in Q3 2025.
AIM ImmunoTech (AIM) Asset Writedowns and Impairment (2011 - 2025) Analysis & Trends
AIM ImmunoTech (AIM) has 4 years of Asset Writedowns and Impairment data on file, last reported at $441000.0 in Q4 2025.
- Quarterly Asset Writedowns and Impairment rose 21950.0% year-over-year to $441000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 624.84% YoY) and the FY2025 annual result came in at $1.1 million, up 2270.83% from the prior year.
- Asset Writedowns and Impairment advanced to $441000.0 in Q4 2025, from $82000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $441000.0 in Q4 2025 to a low of $2000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 441,000.00 |
| Dec 31, 2025 | 441,000.00 |
| Sep 30, 2025 | 82,000.00 |
| Sep 30, 2025 | 82,000.00 |
| Jun 30, 2025 | 280,000.00 |
| Jun 30, 2025 | 280,000.00 |
| Mar 31, 2025 | 335,000.00 |
| Mar 31, 2025 | 335,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Mar 31, 2019 | 344,000.00 |
| Mar 31, 2019 | 344,000.00 |
| Dec 31, 2011 | -189,000.00 |
| Dec 31, 2011 | -189,000.00 |